Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.52 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060857 | 0.88 | CRBN (0.55) | CRBNGLO1PTGES2ACLYBRD4 | |
| SCHEMBL3060506 | 0.87 | CRBN (0.54) | CRBNPTGES2DYRK1ACA12CA1 | |
| SCHEMBL3068945 | 0.87 | CRBN (0.54) | CRBNSLC40A1BRD4DYRK1ACA12 | |
| SCHEMBL21218304 | 0.85 | CRBN (0.60) | CRBNGLO1SLC40A1PTGES2ACLY | |
| SCHEMBL3065955 | 0.84 | CRBN (0.51) | CRBNGLO1DYRK1ACA12CA1 | |
| SCHEMBL3066512 | 0.83 | DDX3X (0.54) | CRBNCA12CA1CA2CA3 | |
| E-7820 SCHEMBL31237463 | 0.83 | CRBN (1.00) | CRBNGLO1SLC40A1PTGES2ACLY | |
| E-7820 SCHEMBL2950395 | 0.83 | CRBN (1.00) | CRBNGLO1SLC40A1PTGES2ACLY | |
| E-7820 SCHEMBL1581157 | 0.83 | CRBN (1.00) | CRBNGLO1SLC40A1PTGES2ACLY | |
| SCHEMBL21218180 | 0.82 | CRBN (0.78) | CRBNGLO1SLC40A1PTGES2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | claimed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
| US-12428459-B2 | Protein tag to induce ligand dependent degradation of protein/protein-fusions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-11807606-B2 | Sulfonamide derivatives for protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220402981-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| EP-4031163-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | Dana-Farber Cancer Institute, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20200290964-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2019147783-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1433479-B1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | EISAI R&D MAN CO LTD (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7015241-B2 | Appetite-stimulating agents and remedies for anorexia | EISAI CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1430894-A1 | LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE | Eisai Co. Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | CRBN 319/4885GLO1 4552/4885SLC40A1 3795/4885 |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | NFATC1, CHUK, CD4 | CRBN 3064/4885GLO1 1180/4885SLC40A1 3066/4885 |
| US-20200290964-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | CUL5, CUL4A, DCAF1 | CRBN 14/4885GLO1 2266/4885SLC40A1 4389/4885 |
| US-11807606-B2 | Sulfonamide derivatives for protein degradation | CUL5, CUL4A, DCAF1 | CRBN 14/4885GLO1 2266/4885SLC40A1 4389/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CRBN 319/4885GLO1 4552/4885SLC40A1 3795/4885 |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | GHSR, CCKAR, SUCNR1 | CRBN 2561/4885GLO1 4441/4885SLC40A1 1573/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | CRBN 810/4885GLO1 4392/4885SLC40A1 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.